Evidence map›Paper›PMID 39657684›Full record

ArticleThe Journal of antimicrobial chemotherapy2025

Ceftolozane/tazobactam disrupts Pseudomonas aeruginosa biofilms under static and dynamic conditions.

Xenia Kostoulias, Ying Fu, Faye C Morris, Crystal Yu, Yue Qu, Christina C Chang, Luke Blakeway, Cornelia B Landersdorfer, Iain J Abbott, Lynn Wang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xenia KostouliasInfection Program, Department of Microbiology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, VIC 3800, Australia.ORCID 0000-0002-8611-2198
Ying FuInfection Program, Department of Microbiology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, VIC 3800, Australia.
Faye C MorrisInfection Program, Department of Microbiology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, VIC 3800, Australia.ORCID 0000-0002-9021-0452
Crystal YuInfection Program, Department of Microbiology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, VIC 3800, Australia.
Yue QuInfection Program, Department of Microbiology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, VIC 3800, Australia.ORCID 0000-0002-4683-708X
Christina C ChangDepartment of Infectious Diseases, The Alfred Hospital and School of Translational Medicine, Monash University, Melbourne, VIC 3004, Australia.
Luke BlakewayDepartment of Infectious Diseases, The Alfred Hospital and School of Translational Medicine, Monash University, Melbourne, VIC 3004, Australia.
Cornelia B LandersdorferCentre to Impact AMR, Monash University, Melbourne, VIC 3800, Australia.ORCID 0000-0003-0928-4743
Iain J AbbottDepartment of Infectious Diseases, The Alfred Hospital and School of Translational Medicine, Monash University, Melbourne, VIC 3004, Australia.ORCID 0000-0001-6590-6127
Lynn WangInfection Program, Department of Microbiology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, VIC 3800, Australia.
Jessica WisniewskiDepartment of Infectious Diseases, The Alfred Hospital and School of Translational Medicine, Monash University, Melbourne, VIC 3004, Australia.
Yunsong YuDepartment of Clinical Laboratory, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.ORCID 0000-0003-2903-918X
Jian LiInfection Program, Department of Microbiology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, VIC 3800, Australia.ORCID 0000-0001-7953-8230
Anton Y PelegInfection Program, Department of Microbiology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, VIC 3800, Australia.

Funding

Merck Sharp & DohmeNational Health and Medical Research Council APP1117940
6 · The paper itself

Abstract

backgroundPseudomonas aeruginosa biofilms limit the efficacy of currently available antibacterial therapies and pose significant clinical challenges. Pseudomonal biofilms are complicated further when other markers of persistence such as mucoid and hypermutable phenotypes are present. There is currently a paucity of data regarding the activity of the newer β-lactam/β-lactamase inhibitor combination ceftolozane/tazobactam against P. aeruginosa biofilms.

methodsWe evaluated the efficacy of ceftolozane/tazobactam against clinical P. aeruginosa isolates, the laboratory isolate PAO1 and its isogenic mutS-deficient hypermutator derivative (PAOMS) grown under static and dynamic biofilm conditions. The clinical isolate collection included strains with mucoid and hypermutable phenotypes.

resultsCeftolozane/tazobactam exposure led to a bactericidal (≥3 log cfu/cm2) biofilm reduction in 15/18 (83%) clinical isolates grown under static conditions, irrespective of carbapenem susceptibility or mucoid phenotype, with greater activity compared with colistin (P < 0.05). Dynamically grown biofilms were less susceptible to ceftolozane/tazobactam with active biofilm reduction (≥1 log cfu/cm2) observed in 2/3 isolates. Hypermutability did not affect the antibiofilm efficacy of ceftolozane/tazobactam in either static or dynamic conditions when comparing PAO1 and PAOMS. Consistent with the activity of ceftolozane/tazobactam as a potent inhibitor of PBP3, dramatic impacts on P. aeruginosa morphology were observed.

conclusionsOur data demonstrate that ceftolozane/tazobactam has encouraging properties in the treatment of P. aeruginosa biofilm infections, and its activity is not diminished against mucoid or hypermutable variants at the timepoints examined.

Indexed as

Anti-Bacterial Agentsbeta-Lactamase InhibitorsBiofilmsCephalosporinsPenicillanic AcidPseudomonas aeruginosaTazobactamHumansMicrobial Sensitivity TestsMicrobial ViabilityPseudomonas InfectionsAnti-Bacterial Agentsbeta-Lactamase Inhibitorsceftolozane, tazobactam drug combinationCephalosporinsPenicillanic AcidTazobactam

Identifiers

PMID39657684
PMCPMC11787898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.